These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 23413416)

  • 1. Septic bursitis, a potential complication of protease inhibitor use in hepatitis C virus.
    Burke CC; Martel-Laferriere V; Dieterich DT
    Clin Infect Dis; 2013 May; 56(10):1507-8. PubMed ID: 23413416
    [No Abstract]   [Full Text] [Related]  

  • 2. Adhesive capsulitis of shoulder and treatment with protease inhibitors in patients with human immunodeficiency virus infection: report of 8 cases.
    Grasland A; Ziza JM; Raguin G; Pouchot J; Vinceneux P
    J Rheumatol; 2000 Nov; 27(11):2642-6. PubMed ID: 11093447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus protease gene diversity in patients coinfected with human immunodeficiency virus.
    Winters MA; Welles SL; Holodniy M
    J Virol; 2006 Apr; 80(8):4196-9. PubMed ID: 16571838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection.
    Fialaire P; Payan C; Vitour D; Chennebault JM; Loison J; Pichard E; Lunel F
    J Infect Dis; 1999 Aug; 180(2):574-5. PubMed ID: 10395889
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of genotype one hepatitis C virus (HCV) infection in HIV co-infected patients using telaprevir based regimen.
    Siraj DS; Kabchi B; Ashraf MS; Shah K; Elnabtity M
    Braz J Infect Dis; 2015; 19(2):226-7. PubMed ID: 25528578
    [No Abstract]   [Full Text] [Related]  

  • 6. Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients.
    Trimoulet P; Belzunce C; Faure M; Wittkop L; Reigadas S; Dupon M; Ragnaud JM; Fleury H; Neau D
    HIV Med; 2011 Sep; 12(8):506-9. PubMed ID: 21410862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The hazard and management strategies of human immunodeficiency virus and hepatitis C virus].
    Guo FP; Li TS
    Zhonghua Nei Ke Za Zhi; 2009 Aug; 48(8):617-9. PubMed ID: 19954048
    [No Abstract]   [Full Text] [Related]  

  • 8. Managing drug-drug interactions in an HIV-infected patient receiving antiretrovirals, anti-HCV therapy and carbamazepine: a 'tour de force' for clinical pharmacologists.
    Burger DM; Arends JE; Jacobs BS; van Elst-Laurijsen DH; de Kanter CT; van Maarseveen EM; Verwey-van Wissen CP; Hoepelman AI
    Int J Antimicrob Agents; 2014 Jul; 44(1):86-8. PubMed ID: 24888870
    [No Abstract]   [Full Text] [Related]  

  • 9. Can boosted atazanavir induce hyperlipotrophy?
    Dellamonica P
    J Infect; 2006 Jun; 52(6):e189-90. PubMed ID: 16239035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prompt arrival of antivirals against hepatitis C for HIV patients.
    Barreiro P; Vispo E
    AIDS Rev; 2010; 12(4):242-3. PubMed ID: 21344779
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of the possible influence of hepatitis C virus and liver fibrosis on HIV type 1 immunological and virological outcomes.
    Collazos J; Cartón JA; Asensi V
    HIV Med; 2011 May; 12(5):308-15. PubMed ID: 20946441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV and hepatitis C coinfection.
    Matthews GV; Rockstroh J
    Curr Opin HIV AIDS; 2011 Nov; 6(6):449-50. PubMed ID: 22001889
    [No Abstract]   [Full Text] [Related]  

  • 13. Lack of benefit of protease inhibitors on HCV viremia in HIV-infected patients.
    Garcia-Samaniego J; Bravo R; Castilla J; Gómez-Cano M; Laguna F; Muñoz F; Soriano V
    J Hepatol; 1998 Mar; 28(3):526-7. PubMed ID: 9580449
    [No Abstract]   [Full Text] [Related]  

  • 14. A study to investigate the impact of the initiation of highly active antiretroviral therapy on the hepatitis C virus viral load in HIV/HCV-coinfected patients.
    Mijch A; Sasadeusz J; Hellard M; Dunne M; McCaw R; Bowden S; Gowans EJ
    Antivir Ther; 2005; 10(2):277-84. PubMed ID: 15865222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adhesive capsulitis of the shoulder induced by protease inhibitor therapy. Three new cases.
    Léone J; Béguinot I; Dehlinger V; Jaussaud R; Rouger C; Strady C; Pennaforte JL; Etienne JC
    Rev Rhum Engl Ed; 1998 Dec; 65(12):800-1. PubMed ID: 9923053
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of hepatitis C 2010: a focus on protease inhibitors.
    Lemon M
    S D Med; 2010 Jun; 63(6):214-5. PubMed ID: 20853592
    [No Abstract]   [Full Text] [Related]  

  • 17. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection.
    Kovari H; Ledergerber B; Battegay M; Rauch A; Hirschel B; Foguena AK; Vernazza P; Bernasconi E; Mueller NJ; Weber R
    Clin Infect Dis; 2010 Feb; 50(4):502-11. PubMed ID: 20085465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interim results presented at EASL from PROVE 1 clinical trial of investigational drug telaprevir in patients with genotype 1 hepatitis C.
    Lang L
    Gastroenterology; 2007 Jun; 132(7):2283-4. PubMed ID: 17570199
    [No Abstract]   [Full Text] [Related]  

  • 19. Coinfection with human immunodeficiency virus and hepatitis C virus: challenges and therapeutic advances. Insights from the Society of Infectious Diseases Pharmacists.
    Deming P; McNicholl IR
    Pharmacotherapy; 2011 Apr; 31(4):357-68. PubMed ID: 21449625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients.
    Stone SF; Lee S; Keane NM; Price P; French MA
    J Infect Dis; 2002 Nov; 186(10):1498-502. PubMed ID: 12404169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.